Weekly ReportOct 12–18, 2026
Sepsis, week 42 edition
We read 241 papers and selected 3.
Summary
This week’s highest-impact sepsis evidence centered on hemodynamic management, prevention, and organ-protective treatment. A large randomized trial showed that intraoperative dobutamine added to norepinephrine reduced postoperative acute kidney injury, while the VASSPR trial found no mortality benefit from initiating vasopressin at a lower vasopressor threshold. A phase 3 ExPEC9V vaccine trial generated a decisive negative result despite strong immunogenicity, demonstrating that antibody responses did not translate into prevention of invasive Escherichia coli disease. Across the broader literature, rapid diagnostics, microbiome and inflammatory endotyping, stewardship safeguards, and molecular targets for organ injury continued to emerge as major research directions.
Selected Articles
1. Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial.
In this multicenter randomized trial of 584 adults with septic shock undergoing surgical source control, intraoperative dobutamine plus norepinephrine reduced new-onset or worsening postoperative acute kidney injury from 34.7% to 22.8% compared with norepinephrine alone. Stage 2 and stage 3 acute kidney injury were also reduced, although tachycardia occurred more frequently with dobutamine.
Impact: This large multicenter randomized trial directly addressed a guideline-supported intervention previously backed by very low-certainty evidence. It provides actionable evidence that perioperative inotropy may protect the kidney during surgical source control, while highlighting the need to monitor for tachycardia.
Clinical Implications: In adults with septic shock undergoing surgical source control, dobutamine added to norepinephrine may reduce postoperative acute kidney injury, particularly when persistent hypoperfusion or cardiac dysfunction is present. Clinicians should balance this potential renal benefit against tachycardia risk and the absence of demonstrated mortality benefit.
Key Findings
- Postoperative new-onset or worsening acute kidney injury occurred in 22.8% with dobutamine plus norepinephrine versus 34.7% with norepinephrine alone.
- Stage 2 and stage 3 acute kidney injury were reduced, with higher early urine output and lower postoperative day 1 SOFA scores in the combination group.
- Tachycardia was more frequent with dobutamine, and mortality or long-term renal benefit was not established.
2. Efficacy, safety, and immunogenicity of a nine-valent vaccine (ExPEC9V) for the prevention of invasive Escherichia coli disease in older adults: a phase 3, randomised, placebo-controlled trial (E.mbrace).
In the multinational phase 3 E.mbrace trial of 17,701 older adults, ExPEC9V produced robust and sustained antibody responses but did not prevent invasive disease caused by vaccine-targeted ExPEC serotypes. Vaccine efficacy was 14.63% with a 95% confidence interval from -106.57% to 65.38%, and the trial was stopped early for futility.
Impact: This large, rigorous phase 3 trial provides a clinically decisive negative result. It demonstrates that immunogenicity is not a sufficient surrogate for protection against invasive ExPEC disease and will redirect vaccine antigen selection, correlates-of-protection research, and future trial design.
Clinical Implications: ExPEC9V should not be used to prevent invasive ExPEC disease because efficacy was not demonstrated and development was discontinued. Prevention should continue to rely on urinary tract infection prevention, early diagnosis, appropriate antimicrobial therapy, and management of underlying risk factors.
Key Findings
- The trial randomized 17,701 older adults: 8,858 to ExPEC9V and 8,843 to placebo.
- There were 11 vaccine-serotype invasive ExPEC disease cases in the vaccine group and 13 in the placebo group.
- Robust antibody responses did not translate into clinical protection, with a prespecified futility analysis supporting early discontinuation.
3. Effect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.
The pragmatic VASSPR cluster-crossover randomized trial included 3,959 patients with septic shock across 13 hospitals and compared lower versus higher norepinephrine-equivalent thresholds for initiating vasopressin. Twenty-eight-day mortality was similar between strategies, providing important evidence against routine early vasopressin initiation solely to improve survival.
Impact: This large pragmatic randomized strategy trial addressed a common bedside decision with substantial practice variation. Its null mortality result challenges the assumption that earlier vasopressin automatically improves outcomes and supports individualized escalation based on shock trajectory and patient phenotype.
Clinical Implications: Starting vasopressin at a lower norepinephrine-equivalent dose should not be expected to reduce 28-day mortality compared with later initiation. Decisions should instead consider shock trajectory, catecholamine toxicity, cardiac function, regional perfusion, adverse effects, and treatment goals.
Key Findings
- The trial included 3,959 unique patients with septic shock across 13 hospitals.
- Twenty-eight-day mortality was 31.8% with the lower-threshold strategy and 33.0% with the higher-threshold strategy.
- Kidney replacement therapy-free days were similar, with no demonstrated mortality benefit from routine lower-threshold initiation.